Physician profile
Devinder Verma
NPI 1811176621
$589.40
in general payments reported to CMS, 2019-2025
11 companies · $206 in 2025
The $206 reported for 2025 was more than what 81% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2021: $28.96 · 2022: $39.76 · 2023: $71.86 · 2024: $139 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $174.02 | 2023-2025 | Movantik |
| Vertex Pharmaceuticals Incorporated | $86.90 | 2025 | |
| Merck Sharp & Dohme LLC | $64.52 | 2019-2025 | Bridion |
| Mallinckrodt Enterprises LLC | $60.56 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.00 | 2021-2024 | Relistor |
| Bioventus LLC | $43.07 | 2022-2023 | Supartz Fx Sodium Hyaluronate |
| Azurity Pharmaceuticals, INC. | $38.49 | 2024-2025 | Horizant |
| Braeburn INC. | $24.37 | 2023 | Brixadi |
| Axsome Therapeutics, INC. | $17.32 | 2025 | Symbravo |
| Redhill Biopharma INC. | $15.92 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.23 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devinder Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.